Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Recenti Progressi in Medicina|March 21, 2012
[Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer]Giacinto Turitto, Maurizio Di Bisceglie, Lucia Moraca, et al.Recenti Progressi in Medicina|July 23, 2011
[Retroperitoneal schwannoma: a case report]Giacinto Turitto, Maurizio Di Bisceglie, Lucia Moraca, et al.Journal of Clinical Medicine|December 17, 2024
Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter StudyPalma Fedele, Matteo Landriscina, Lucia Moraca, et al.Cancers|October 29, 2025
CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2- Metastatic Breast Cancer: A Real-World Multicenter StudyPalma Fedele, Matteo Landriscina, Lucia Moraca, et al.Cancers|October 26, 2024
Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter StudyPalma Fedele, Matteo Landriscina, Lucia Moraca, et al.Journal of Clinical Medicine|December 30, 2025
BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisPalma Fedele, Alessandro Rizzo, Matteo Landriscina, et al.Cancers|November 13, 2025
Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisPalma Fedele, Stefania Luigia Stucci, Matteo Landriscina, et al.Breast Cancer Research and Treatment|July 10, 2026
Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world studyPalma Fedele, Alessandro Rizzo, Matteo Landriscina, et al.Pageof 1